JP2021505663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505663A5 JP2021505663A5 JP2020548894A JP2020548894A JP2021505663A5 JP 2021505663 A5 JP2021505663 A5 JP 2021505663A5 JP 2020548894 A JP2020548894 A JP 2020548894A JP 2020548894 A JP2020548894 A JP 2020548894A JP 2021505663 A5 JP2021505663 A5 JP 2021505663A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- dclk1
- antibody
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 71
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 150000007523 nucleic acids Chemical group 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 210000002865 immune cell Anatomy 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims description 11
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 108091033409 CRISPR Proteins 0.000 claims description 3
- 238000010354 CRISPR gene editing Methods 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- -1 4-IBB (CD137) Proteins 0.000 claims description 2
- 101710145634 Antigen 1 Proteins 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 238000002823 phage display Methods 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023151660A JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594464P | 2017-12-04 | 2017-12-04 | |
| US62/594,464 | 2017-12-04 | ||
| PCT/US2018/063702 WO2019112978A2 (en) | 2017-12-04 | 2018-12-03 | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151660A Division JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505663A JP2021505663A (ja) | 2021-02-18 |
| JP2021505663A5 true JP2021505663A5 (enExample) | 2022-01-11 |
| JP7409669B2 JP7409669B2 (ja) | 2024-01-09 |
Family
ID=66751211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548894A Active JP7409669B2 (ja) | 2017-12-04 | 2018-12-03 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
| JP2023151660A Pending JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151660A Pending JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12084514B2 (enExample) |
| EP (1) | EP3720481A4 (enExample) |
| JP (2) | JP7409669B2 (enExample) |
| CN (1) | CN111818939B (enExample) |
| CA (1) | CA3122010A1 (enExample) |
| WO (1) | WO2019112978A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| KR102344616B1 (ko) | 2017-05-30 | 2021-12-31 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 항-더블코르틴-유사 키나제 1 항체 및 사용 방법 |
| EP3720481A4 (en) * | 2017-12-04 | 2021-10-13 | Coare Holdings, Inc. | ANTI-DCLK1 ANTIBODIES AND CHIMERA ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THEREOF |
| JP7627255B2 (ja) | 2019-07-08 | 2025-02-05 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルムを破壊するための抗体組成物 |
| WO2021046331A1 (en) * | 2019-09-05 | 2021-03-11 | Memorial Sloan Kettering Cancer Center | Anti-steap1 antibodies and uses thereof |
| WO2024118940A1 (en) * | 2022-12-01 | 2024-06-06 | Twist Bioscience Corporation | Anti-psma antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2470941C2 (ru) | 2005-12-02 | 2012-12-27 | Дженентек, Инк. | Связывающие полипептиды и их применения |
| WO2008030543A2 (en) * | 2006-09-08 | 2008-03-13 | Cell Signaling Technology, Inc. | Tyrosine, serine and threonine phosphorylation sites |
| US7902166B2 (en) | 2008-04-03 | 2011-03-08 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
| US8936941B2 (en) | 2008-04-03 | 2015-01-20 | The Board Of Regents Of The University Of Oklahoma | Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof |
| US9663585B2 (en) * | 2008-05-16 | 2017-05-30 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 monoclonal antibodies and methods of production and use thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2831119A1 (en) | 2012-03-28 | 2015-02-04 | F. Hoffmann-La Roche AG | Anti-hcmv idiotypic antibodies and uses thereof |
| KR20160046914A (ko) | 2013-08-28 | 2016-04-29 | 스템센트알엑스 인코포레이티드 | 신규한 ｓｅｚ6 조절물질 및 사용방법 |
| PT3218406T (pt) * | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Moléculas de ligação específicas para cd73 e seus usos |
| EP4276116A3 (en) * | 2015-04-17 | 2024-01-17 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
| US9822184B2 (en) | 2015-04-22 | 2017-11-21 | The Board Of Regents Of The University Of Texas System | DCLK1 short form specific binding agents |
| KR102344616B1 (ko) * | 2017-05-30 | 2021-12-31 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 항-더블코르틴-유사 키나제 1 항체 및 사용 방법 |
| EP3720481A4 (en) | 2017-12-04 | 2021-10-13 | Coare Holdings, Inc. | ANTI-DCLK1 ANTIBODIES AND CHIMERA ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THEREOF |
-
2018
- 2018-12-03 EP EP18885373.3A patent/EP3720481A4/en active Pending
- 2018-12-03 WO PCT/US2018/063702 patent/WO2019112978A2/en not_active Ceased
- 2018-12-03 CN CN201880087617.8A patent/CN111818939B/zh active Active
- 2018-12-03 US US16/769,567 patent/US12084514B2/en active Active
- 2018-12-03 CA CA3122010A patent/CA3122010A1/en active Pending
- 2018-12-03 JP JP2020548894A patent/JP7409669B2/ja active Active
-
2023
- 2023-09-19 JP JP2023151660A patent/JP2023165793A/ja active Pending
-
2024
- 2024-01-30 US US18/427,038 patent/US12415867B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505663A5 (enExample) | ||
| JP7253020B2 (ja) | キメラ抗原受容体およびその使用 | |
| JP7061235B2 (ja) | 抗ｃｌｄ１８ａ２ナノ抗体及びその応用 | |
| CN110121505B (zh) | 嵌合抗原受体和表达其的自然杀伤细胞 | |
| US11382963B2 (en) | Engineered T cells and uses therefor | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7222600B2 (ja) | 腫瘍細胞に特異的なキメラ抗原レセプター | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| CN110214152B (zh) | 模块化四聚体双特异性抗体平台 | |
| JP2022500419A (ja) | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 | |
| JP2018529380A5 (enExample) | ||
| CN110035768A (zh) | 嵌合抗原受体 | |
| CN112469829A (zh) | 包含抗gpc3单链抗体的car | |
| JP2018513687A5 (enExample) | ||
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| JP2020501512A5 (enExample) | ||
| WO2018132513A1 (en) | T cells experessing a chimeric antigen receptor | |
| JP2018518151A5 (enExample) | ||
| JP2024501888A (ja) | Ｂｃｍａに特異的に結合する抗体およびその使用 | |
| US12251447B2 (en) | Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer | |
| JP7619682B2 (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| CN113549155A (zh) | 同时靶向cd19和cd20的嵌合抗原受体及其应用 | |
| CN118108845B (zh) | 一种靶向B7-H3的CAR-γδT细胞的制备方法及应用 | |
| US20240342281A1 (en) | Use of a stromal antigen to deliver cell-based cancer therapy to a solid tumor | |
| KR102904082B1 (ko) | 항종양제 및 그 평가방법 |